EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2-Reference-Cited by-同舟云学术

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

Published:2019-12-19 Issue:25 Volume:134 Page:2261-2270
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cristino Alexandre S.¹²^ORCID,Nourse Jamie³,West Rachael A.²^ORCID,Sabdia Muhammed Bilal⁴,Law Soi C.⁴^ORCID,Gunawardana Jay⁴^ORCID,Vari Frank³,Mujaj Sally³,Thillaiyampalam Gayathri²,Snell Cameron⁴⁵^ORCID,Gough Madeline⁴⁵,Keane Colm⁴⁶,Gandhi Maher K.⁴⁶^ORCID

Affiliation:

1. Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia;

2. Diamantina Institute, University of Queensland, Brisbane, QLD, Australia;

3. Queensland Institute of Medical Research, Brisbane, QLD, Australia;

4. Mater Research, University of Queensland, Brisbane, QLD, Australia;

5. Mater Pathology, Brisbane, QLD, Australia; and

6. Princess Alexandra Hospital, Brisbane, QLD, Australia

Abstract

This article reports a novel mechanism by which Epstein-Barr virus (EBV) microRNA (miRNA) plays a role to fine-tune the expression of LMP1-driven amplification of inhibitory checkpoint programmed death ligand 1 (PD-L1) and PD-L2 in EBV+ diffuse large B-cell lymphoma. Identification and understanding of the immune checkpoint regulation via miRNA may enable potential novel RNA-based therapies to emerge.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/25/2261/1549315/bloodbld2019000889.pdf

Reference72 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

2. Persistence of the Epstein-Barr virus and the origins of associated lymphomas;Thorley-Lawson;N Engl J Med,2004

3. EBV-positive diffuse large B-cell lymphoma of the elderly;Ok;Blood,2013

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and prospects of RNA delivery nanoplatforms for cancer therapy;Acta Pharmaceutica Sinica B;2024-09

2. EBV + B cell-derived exosomes promote EBV-associated T/NK-cell lymphoproliferative disease immune evasion by STAT3/IL-10/PD-L1 pathway;Immunologic Research;2024-08-20

3. Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma;American Journal of Hematology;2024-08-17

4. The IRE1α Endonuclease Plays a Dual Role in Regulating the XBP1/miRNA-34a Axis and PD-1 Expression within Natural Killer Cells in Hodgkin Lymphoma;Acta Haematologica;2024-03-14

5. Carcinogenic mechanisms of virus-associated lymphoma;Frontiers in Immunology;2024-02-28